Clinical Trials

1,314 enrolled 23 charts 1 FDA

Urothelial Cancer

NCT02811861 2026-02-23

CLEAR

1,069 enrolled 12 charts 1 FDA

Carcinoma, Renal Cell

NCT04689828 2026-02-20

PSMAfore

469 enrolled 11 charts 1 FDA

Prostatic Neoplasms

NCT04497844 2026-02-13

AMPLITUDE

696 enrolled 15 charts 1 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT01946204 2026-02-02

SPARTAN

1,207 enrolled 15 charts 1 FDA

Prostatic Neoplasms

NCT02489318 2026-02-02

TITAN

1,052 enrolled 13 charts 1 FDA

Prostatic Neoplasms

NCT02853331 2026-02-02

KEYNOTE-426

861 enrolled 24 charts 1 FDA

Carcinoma, Renal Cell

NCT03390504 2026-02-02

THOR

629 enrolled 32 charts 1 FDA

Phase 2 Active not recruiting

Urothelial Cancer

NCT02365597 2026-01-30

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

239 enrolled 32 charts 1 FDA

Urothelial Cancer

NCT02003924 2026-01-27

PROSPER

1,401 enrolled 25 charts 1 FDA

Prostatic Neoplasms

NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

608 enrolled 22 charts 1 FDA

Phase 1/2 Active not recruiting

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT02650401 2025-12-24

STARTRK-NG

69 enrolled 1 FDA

CNSEndocrineGenitourinaryHead & NeckSarcoma

Thyroid Cancer, Papillary, Brain Neoplasms, Glioma, Medulloblastoma, Neoplasm Metastasis, Wilms Tumor, Neuroblastoma, Recurrence, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Ewing, Central Nervous System Neoplasms, Nephroma, Mesoblastic

NCT03288545 2025-11-10

EV-103

Phase 1/2 Active not recruiting

348 enrolled 1 FDA

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT02677896 2025-10-24

ARCHES

1,150 enrolled 23 charts 1 FDA

Phase 2/3 Active not recruiting

Metastatic Hormone Sensitive Prostate Cancer

NCT03022825 2025-10-16

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

190 enrolled 1 FDA

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04810078 2025-10-09

CheckMate-67T

681 enrolled 1 FDA

Carcinoma, Renal Cell

NCT02684006 2025-07-30

JAVELIN Renal 101

886 enrolled 37 charts 1 FDA

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

NCT02319837 2025-07-08

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

1,068 enrolled 20 charts 1 FDA

Prostatic Neoplasms

NCT02231749 2025-06-26

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

1,390 enrolled 18 charts 1 FDA

Carcinoma, Renal Cell

NCT04223856 2025-06-13

EV-302

886 enrolled 12 charts 1 FDA

Urothelial Cancer

NCT03141177 2025-06-06

CheckMate 9ER

701 enrolled 17 charts 1 FDA

Carcinoma, Renal Cell

NCT04195750 2025-04-29

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

755 enrolled 28 charts 1 FDA

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01715285 2025-02-04

A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)

1,209 enrolled 16 charts 1 FDA

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT03212404 2025-02-03

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

272 enrolled 1 FDA

DermatologicGenitourinaryGynecologicHead & NeckLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasms, Skin Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Carcinoma, Small Cell

NCT03511664 2025-01-13

VISION

861 enrolled 39 charts 1 FDA

Prostatic Neoplasms

NCT05243550 2024-11-04

ENVISION

240 enrolled 20 charts 1 FDA

219 enrolled 32 charts 2 FDA

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03219333 2024-08-27

EV-201

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT02773849 2024-07-29

ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

157 enrolled 22 charts 1 FDA

Non-Muscle Invasive Bladder Neoplasms

NCT02603432 2024-03-27

JAVELIN Bladder 100

700 enrolled 35 charts 2 FDA

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT02987543 2023-10-06

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

387 enrolled 16 charts 2 FDA

Metastatic Castration-resistant Prostate Cancer

NCT02627963 2023-07-18

A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)

350 enrolled 14 charts 1 FDA

Carcinoma, Renal Cell

NCT02200614 2022-06-28

ARAMIS

1,509 enrolled 13 charts 1 FDA

Prostate Cancer Non-Metastatic

NCT03085095 2022-01-18

HERO

1,134 enrolled 38 charts 2 FDA

515 enrolled 28 charts 2 FDA

Prostatic Neoplasms

NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Phase 1/2 Completed

BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01835158 2021-02-11

Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer

Phase 2 Completed

157 enrolled 10 charts 1 FDA

Carcinoma, Renal Cell

NCT02793128 2020-12-22

Olympus

71 enrolled 16 charts 2 FDA

Carcinoma, Carcinoma, Transitional Cell

NCT00375674 2018-09-21

S-TRAC

674 enrolled 19 charts 1 FDA